Disease · MONDO_0800207
neuropathy, small fiber
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. neuropathy, small fiber. Diseases, record MONDO_0800207. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0800207
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- neuropathy, small fiber
- Open Targets ID
- MONDO_0800207
- Other names
- SFNP
- Highest stage of its drugs
- Phase 2, for 4 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PREGABALIN | CHEMBL1059 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CIBINETIDE | CHEMBL3545305 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PERAMPANEL | CHEMBL1214124 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VIXOTRIGINE | CHEMBL3544913 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELCUBRAGISTAT | CHEMBL3945728 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets34
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1A | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/773 | Drugs and targets |
| CACNA1B | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CACNA1C | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1E | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/777 | Drugs and targets |
| CACNA1F | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1G | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8913 | Drugs and targets |
| CACNA1H | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8912 | Drugs and targets |
| CACNA1I | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8911 | Drugs and targets |
| CACNA1S | Voltage-gated calcium channel | 1 | Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/779 | Drugs and targets |
1 to 10 of 34
See all 34 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02039687 | Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Phase 2 | 64 | 2017-01-18 | Neuropathy of Sarcoidosis | CIBINETIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02607254 | Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy | Phase 2 | 11 | 2018-10-04 | Idiopathic Small Fiber Neuropathy | PREGABALIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03339336 | Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | Phase 2 | 265 | Small Fiber Neuropathy, Diabetes Mellitus | VIXOTRIGINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03447756 | Titration Study of ABX-1431 | Phase 1 | 39 | Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy, Small Fiber Neuropathy, Post-Traumatic Neuralgia | ELCUBRAGISTAT | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02511873 | Fycompa in Subjects With Small Fiber Neuropathy (SFN) | Phase 2 | 30 | Neuropathy, Small Fiber | PERAMPANEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00787462 | Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy | Not applicable | 3 | Small-Fiber Neuropathy | PREGABALIN | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 37152360 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0800207
GET https://conductscience.org/api/diseases/v1/MONDO_0800207/targets?page=2